Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; magnesium stearate; crospovidone; hypromellose; indigo carmine; titanium dioxide; macrogol 400; povidone - levetiracetam film-coated tablets are indicated for: ? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation, ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and ? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - levetiracetam, quantity: 750 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; povidone; sunset yellow fcf; iron oxide red; purified talc; macrogol 400; titanium dioxide; colloidal anhydrous silica; magnesium stearate - levetiracetam film-coated tablets are indicated for: ? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation, ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and ? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; povidone; magnesium stearate; hypromellose; iron oxide yellow; titanium dioxide; purified talc; crospovidone; macrogol 400 - levetiracetam film-coated tablets are indicated for: ? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation, ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and ? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: indigo carmine; macrogol 400; titanium dioxide; magnesium stearate; purified talc; hypromellose; povidone; colloidal anhydrous silica; crospovidone - levetiracetam film-coated tablets are indicated for: ? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation, ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and ? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: iron oxide yellow; crospovidone; hypromellose; colloidal anhydrous silica; purified talc; povidone; titanium dioxide; macrogol 400; magnesium stearate - levetiracetam film-coated tablets are indicated for: ? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation, ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and ? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - levetiracetam - film-coated tablet - levetiracetam 250 mg - antiepileptics

Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - levetiracetam - film-coated tablet - levetiracetam 500 mg - antiepileptics

Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - levetiracetam - film-coated tablet - levetiracetam 750 mg - antiepileptics

Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - levetiracetam - film-coated tablet - levetiracetam 1000 mg - antiepileptics

Australia - English - Department of Health (Therapeutic Goods Administration)

adiramedica pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; croscarmellose sodium; copovidone; magnesium stearate; purified talc; titanium dioxide; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake; polysorbate 80; macrogol 4000 - levetiracetam is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and ? add-on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).